NTN Buzztime, Inc. and Brooklyn ImmunoTherapeutics LLC Enter into Definitive Merger Agreement

-Proposed merger will create a public company focused on the clinical development program of a cytokine-based product for the treatment of cancer
-Combined company expected to trade on the NYSE American under a new ticker symbol
-Brooklyn already has $10 million of funding committed for post-merger activities
CARLSBAD, Calif. and BROOKLYN, N.Y., Aug. 13, 2020 /PRNewswire/ — NTN Buzztime, Inc. (NYSE American: NTN) and Brooklyn ImmunoTherapeutics LLC (“Brooklyn”), a privately-held biopharmaceu…

Click here to view the original article.